This paper analyses preliminary results of a randomised chemoprevention trial in patients surgically treated for oral leukoplakia started in 1988 at the Istituto Nazionale Tumori of Milan with the synthetic retinoid N-(4-hydroxyphenyl)-retinamide (4-HPR). To date 115 patients have been randomised, after surgical excision of oral leukoplakia, to receive 200 mg 4-HPR daily for 52 weeks versus no intervention. 80 patients completed the 1-year intervention, 41 in the control group and 39 in the 4-HPR group. During this period 12 local relapses or new lesions occurred in the control group and three in the 4-HPR group. Only 5 patients interrupted the intervention because of toxicity. No impaired dark adaptation was observed. It is concluded that 4-HPR is well tolerated and seems efficacious in preventing relapses and new localisations during the treatment period. This promising trend needs further confirmation.
Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results / F. Chiesa, N. Tradati, M. Marazza, N. Rossi, P. Boracchi, L. Mariani, M. Clerici, F. Formelli, L. Barzan, A. Carrassi. - In: EUROPEAN JOURNAL OF CANCER. PART B, ORAL ONCOLOGY. - ISSN 0964-1955. - 28B:2(1992 Oct), pp. 97-102-102.
|Titolo:||Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results|
|Parole Chiave:||Leukoplakia, Oral; Postoperative Care; Humans; Adult; Aged; Middle Aged; Neoplasm Recurrence, Local; Fenretinide; Male; Female|
|Settore Scientifico Disciplinare:||Settore MED/01 - Statistica Medica|
Settore MED/28 - Malattie Odontostomatologiche
|Data di pubblicazione:||ott-1992|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/0964-1955(92)90035-Y|
|Appare nelle tipologie:||01 - Articolo su periodico|